Preventive cardiovascular care
Applications of Spirulysat® in prevention of cardiovascular diseases
Spirulysat® is the emblematic product of AlgoSource, obtained thanks to a unique and patented process of cold-water extraction, without solvents or chemicals. Performed without any heat treatment, this exclusive process makes it possible to isolate the most powerful active ingredients from spirulina and retain all their original properties.
Spirulysat® is, thus, a pure complex of the molecules of interest in spirulina. Among these, phycocyanins are at the heart of this extract of high added value.
Today, the technological mastery that AlgoSource has been able to develop allows it to dose its phycocyanin extracts on demand, thereby offering cutting-edge health applications, prevention of pathologies or supportive care, in addition to curative medication protocols to support the quality of life of patients.
For almost 10 years, AlgoSource has worked with the Centre de Recherche en Nutrition Humaine (CRNH) Grand Ouest, which is part of the Nantes University Hospital and the INRA, as well as with the Biofortis laboratory of the Biomérieux group. It is with these laboratories that the antioxidant activity of Spirulysat® and specific health applications have been demonstrated.
Prevention of atherosclerosis
Atherosclerosis is a disease caused by accumulation, in the internal walls of the arteries, of lipid debris and fibrous tissue leading to the formation of an atheromatous plaque, also called atheroma, which narrows the arteries and restricts blood flow.
Atherosclerosis is one of the leading causes of disability and vascular death worldwide.
The risks of developing atherosclerosis are genetic and/or intrinsically linked to our modern lifestyle: smoking, alcohol consumption, obesity, sedentary lifestyle, stress, etc. Thus, this it represents a real threat for public health.
Several therapeutic strategies targeting risk factors can be used to limit the aggravation during atherosclerosis, but prevention remains the most effective strategy to counter the development of this disease.
AlgoSource, with the help of CRNH Grand Ouest, has successfully demonstrated the preventive action of its spirulina extract, Spirulysat®, combined with a significant dose effect, to prevent the formation of atheroma plaques, thereby reducing the risk of this cardiovascular pathology.
This study made it possible to demonstrate a preventive action both on subjects who developed atherosclerosis during their existence as well as on subjects in-utero thanks to ingestion of Spirulysat® by the mother during gestation.
Therefore, Spirulysat® has proven effective for prevention from this dual perspective.
Bolstered by these results, AlgoSource has filed a patent for this specific applicative use.
Do you have a question?
Contact our team
Do you want to know more about our products, our ingredients from microalgae and our know-how? Contact us!